Median pancreatectomy (MP) has gained popularity in the past decade as treatment of choice for benign and low-malignant potential tumor in the mid-pancreas due to its ability to achieve optimal preservation of pancreatic parenchyma. MP is a safe and effective alternative to major pancreatic resection in selected patients with benign or low-malignant lesions of the pancreas. This paper reports a case of successful MP done for a lesion at the junction of neck and body of pancreas in a rural medical college in India. Post-operative follow up for 2 years showed complete relief of abdominal symptoms with good exocrine and endocrine function.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811819 | PMC |
http://dx.doi.org/10.1007/s13193-015-0439-3 | DOI Listing |
J Am Coll Surg
January 2025
Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
Introduction: Pathway-driven, post-pancreatectomy opioid reduction interventions have proven effective and sustainable and may have a "halo effect" on other major abdominal cancer operations. This study's aim was to analyze the sequential effects of expanding opioid reduction efforts from pancreatectomy on opioids prescribed after hepatectomy.
Methods: This is a retrospective cohort study utilizing data from the electronic health record and a prospective quality improvement database for consecutive hepatectomy patients (09/2016-02/2024).
BMC Cancer
January 2025
Department of Physical Therapy, Faculty of Medical Science, Nagoya Women's University, 3-4-0 Shioji-cho, Mizuho-ku, Nagoya, 467-8610, Aichi, Japan.
Background: Despite advances in treatment, the incidence of postoperative complications following pancreatectomy remains high, leading to frequent hospital readmissions. Therefore, this study aimed to investigate the relationship between preoperative exercise tolerance and the likelihood of unplanned readmission in patients with pancreatic ductal adenocarcinoma.
Methods: This retrospective analysis included 88 patients who underwent pancreatectomy at a single institution between July 2019 and September 2022 and focused on patients with pancreatic ductal adenocarcinoma.
J Am Coll Surg
January 2025
Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH.
Introduction: We aimed to investigate the geographic variation of Academic Medical Centers (AMCs) across different healthcare markets and the impact on surgical outcomes in nearby non-AMCs.
Methods: Patients who underwent major surgery between 2016 and 2021 were identified from the Medicare Standard Analytic Files. Healthcare markets were delineated using Dartmouth Atlas hospital referral regions.
J Surg Oncol
January 2025
Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK.
Introduction: Pancreatic ductal adenocarcinoma (PDAC) of the body/tail is notably different than PDAC in the head of the pancreas. Surgery plus chemotherapy is known to improve outcomes for all PDAC. The sequence of this therapy is well studied in head cancers yet has never been evaluated systematically in relation to distal pancreatectomy (DP).
View Article and Find Full Text PDFHPB (Oxford)
December 2024
Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Lausanne, Switzerland. Electronic address:
Background: Enhanced Recovery After Surgery (ERAS) protocols decrease postoperative complications, but data on their effect on diabetic patients undergoing pancreatectomy are scarce. This study assessed whether diabetes mellitus (DM) was a morbidity predictor after pancreatectomy within an ERAS program.
Methods: A cross-sectional study including all patients who underwent pancreatectomy (2012-2022) and followed an ERAS pathway was performed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!